GlaxoSmithKline News and Research

RSS

Participants in antidepressant drug trials are atypical patients

One reason antidepressant medication treatments do not work as well in real life as they do in clinical studies could be the limited type of study participants selected, researchers at UT Southwestern Medical Center have found.

12 May 2009

GSK to divest U.S. rights for Wellbutrin XL to Biovail

GlaxoSmithKline has announced that it has entered into an agreement to divest full commercial rights to Wellbutrin XL in the United States to Biovail International Laboratories SRL, a subsidiary of Biovail Corporation, for $510 million (euro 340 million). The agreement is subject to Hart-Scott-Rodino regulatory clearance in the United States.

6 May 2009

New antidepressants might be no more effective than the best existing drugs

The reviews suggest that sertraline - sold under the brand name Zoloft since 1991- could be the best initial choice of antidepressant in people with acute major depression. The generic formulation produced the best balance of effectiveness, tolerability and purchase price, the authors say.

5 May 2009

GlaxoSmithKline and Pfizer team up to form HIV company

Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company.

16 Apr 2009

Colon cancer shuts down receptor that could shut it down

Though a high-fiber diet has long been considered good for you and beneficial in staving off colon cancer, Medical College of Georgia researchers have discovered a reason why: roughage activates a receptor with cancer-killing potential.

13 Apr 2009

New small molecule approach to Alzheimer's disease treatment

New therapeutic approaches in Alzheimer's disease are urgently needed.

13 Apr 2009

Experimental vaccine shows promise for the treatment of early lung cancer

An experimental vaccine that triggers the patient's immune system to identify and attack specific tumor cells is showing new promise for the treatment of early lung cancer.

6 Apr 2009

FDA warns 14 pharmaceutical companies about short internet ads lacking risk information

FDA has warned 14 major pharmaceutical firms about brief Internet advertisements that could have misled patients because they did not include information about health risks related to the drugs, according to letters posted to the agency's Web site Friday, the Wall Street Journal reports.

6 Apr 2009

Schizophrenia could be caused by faulty signalling in the brain

In the biggest study of its kind, scientists looking in detail at brain samples donated by people with the condition have identified 49 genes that work differently in the brains of schizophrenia patients compared to controls.

2 Apr 2009

NEJM Letters respond to recent studies on malaria vaccines, treatments

The New England Journal of Medicine in its March 19 issue featured a letter to the editor written in response to a study published in its Dec. 11 issue reporting the results of the RTS,S/AS01E malaria vaccine trial.

23 Mar 2009

Alzheimer's disease neuroimaging initiative announces completion of genome-wide analysis

Researchers announced today that a high-density genome wide analysis of participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI; www.adni-info.org) is more than 95% complete and that data will be shared with scientists around the world for further analysis.

16 Mar 2009

Faulty signalling in the brain may cause schizophrenia

3 Mar 2009

Mindset BioPharmaceuticals receives notice of allowance for European patent related to insulin sensitizers in dementia and memory loss

Mindset BioPharmaceuticals (USA) Inc ("MINDSET") a company privately held by MPM Capital and other shareholders announced today that it has received a Notice of Allowance in Europe related to patent applications describing the use of insulin sensitizer drugs for the prevention and treatment of memory loss.

24 Feb 2009

GlaxoSmithKline starts phase III trial of Syncria (albiglutide) type 2 diabetes medication

GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria (albiglutide) in men and women with type 2 diabetes.

18 Feb 2009

First data released on genetic basis of adverse drug events

The first data offering health care professionals a better look into the genetic basis of certain types of adverse drug events was released today by the FDA and the International Serious Adverse Event Consortium (SAEC).

10 Feb 2009

Idenix Pharmaceuticals and GSK sign agreement for novel NNRTI for treatment of HIV

Idenix Pharmaceuticals, Inc. and GlaxoSmithKline (GSK) today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899.

8 Feb 2009

New imaging technique catches arthritis early

You come into a doctor's office with severe knee pain. The physician orders an MRI, which reveals substantial loss of cartilage - osteoarthritis, that is - in your knee joint. At this point, not much can be done beyond gulping down palliatives and trying to keep your weight off the joint. But the damage may have started building as much as 20 years earlier, possibly due to a traumatic injury to the affected joint.

29 Jan 2009

GSK and XenoPort resubmit NDA for Solzira in restless legs syndrome

GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

12 Jan 2009

GSK completes tender offer for shares of Genelabs Technologies

GlaxoSmithKline plc has announced the successful completion of the tender offer by its wholly-owned subsidiary Gemstone Acquisition Corporation for shares of common stock of Genelabs Technologies, Inc.

7 Jan 2009

Nicotine gum effective for gradual smoking reduction and cessation

Nicotine gum has been in use for over 20 years to help smokers quit abruptly yet close to two-thirds of smokers report that they would prefer to quit gradually.

6 Jan 2009